Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-mercaptopurine plus low-dose methotrexate in BRCA-defective breast or ovarian cancer
ISRCTN63150635Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of mercaptopurine and methotrexate in breast cancer and ovarian cancer, sponsored by University of Oxford. Primary endpoint: Objective tumour response rate. Started Apr 2011; status: completed.
02
Drugs
mercaptopurinemethotrexate
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on ISRCTN63150635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63150635.